Advertisement

Sligo Health and Policy Updates: Kingsbridge Hospital Talks and Drug Access

Popular Posts

Advertisement
Group of Kingsbridge Hospital staff members standing outside the hospital entrance holding a sign

Quick Read

  • Kingsbridge Hospital group is reviewing its care model in Sligo, raising concerns over 83 staff positions.
  • The Oireachtas committee has backed the reimbursement of Givinostat for Duchenne Muscular Dystrophy.
  • Givinostat treatment costs between €92,000 and €334,000 per patient annually.

A high-level delegation from the Kingsbridge Hospital group met with Sligo-Leitrim Junior Ministers at Leinster House today to address growing concerns regarding the future of the Sligo facility. Following internal discussions between staff and management last week, fears have mounted over potential redundancies linked to a proposed new care model. With 83 staff members currently employed at the site, local representatives are seeking clarity on the scale of potential workforce reductions. A formal statement from the meeting is expected later this afternoon.

Advertisement

Separately, the Oireachtas Committee on Drugs Use has formally recommended the approval of ‘Givinostat,’ a treatment for Duchenne Muscular Dystrophy. The condition, a genetic disorder causing progressive muscle weakness, impacts several children in the region, including Aaron Langan from south Donegal. While the drug received EU approval in June 2025, it had previously been denied reimbursement in Ireland due to cost-effectiveness concerns cited by the National Centre for Pharmacoeconomics. With annual costs per patient estimated between €92,000 and €334,000, the committee’s recommendation marks a significant step toward potential state funding for affected families.

LATEST NEWS

Advertisement